FDA puts Pluristem's PLX-PAD Phase II trial on hold

Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) slid on Tuesday after FDA placed a clinical hold on a U.S. Phase II trial of PLX-PAD -- allogeneic, placental-derived expanded (PLX) ...